1. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer
- Author
-
Xiaolin Guan, Yanchun Wang, Lin Guo, Keyu Zhu, Hui Zheng, Yixuan Liu, Renquan Lu, Suhong Xie, and Ying Tong
- Subjects
endocrine system diseases ,medicine.medical_treatment ,Cell Cycle Proteins ,Drug resistance ,Protein Serine-Threonine Kinases ,Ovarian cancer ,medicine ,Humans ,PI3K/AKT/mTOR pathway ,Cisplatin resistance ,Cisplatin ,Ovarian Neoplasms ,Chemotherapy ,Akt/PKB signaling pathway ,business.industry ,Signaling pathway ,Research ,Obstetrics and Gynecology ,Gynecology and obstetrics ,Protein-Tyrosine Kinases ,medicine.disease ,female genital diseases and pregnancy complications ,Oncology ,RG1-991 ,Cancer research ,Female ,Signal transduction ,business ,Tyrosine kinase ,Threonine and tyrosine kinase (TTK) ,medicine.drug - Abstract
Background Drug resistance and recurrence are main contributors to the poor prognosis of ovarian cancer. Cisplatin is a platinum compound which is widely used in the treatment of various solid tumors including ovarian cancer. Up to now, the mechanism of cisplatin resistance in ovarian cancer is unclear. Threonine and tyrosine kinase (TTK), an integral part of the spindle assembly checkpoint, may be a potential new target associated with chemotherapy sensitivity. Results TTK was up-regulated in the cisplatin-resistant ovarian cancer cell line. Down-regulation of TTK could recover the sensitivity of cisplatin-resistant ovarian cancer cells to cisplatin treatment. Mechanistically, the PI3K/AKT signaling pathway was activated in cisplatin-resistant cells, and this pathway would be affected by TTK expression. Furthermore, TTK was highly expressed in the tissues of ovarian cancer patients, especially those acquired resistance to cisplatin. Conclusions Our study revealed that TTK may be a promising therapeutic target for cisplatin-resistant ovarian cancer.
- Published
- 2021